Indeed, most CLL patients mounted a SARS-CoV-2-specific antibody response, with 94.7% (n = 36) positive for IgG and 89.5% (n = 34) for IgA. This evidence concerns the gene CD79A and B-cell chronic lymphocytic leukemia.